Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Show me how to use this page

Regeneron Pharmaceuticals Inc. Stock

Price
Target price
€660.60

€660.60

-2.650%
-17.8
-2.650%
€705.36
 
02.04.26 / Tradegate WKN: 881535 / Symbol: REGN / Name: Regeneron / Stock / Biotechnology & Medical Research / Large Cap /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Regeneron Pharmaceuticals Inc. in the next few years
Wizard

Regeneron Pharmaceuticals Inc. Stock

A loss of -2.650% shows a downward development for Regeneron Pharmaceuticals Inc..
The stock is one of the favorites of our community with 44 Buy predictions and 1 Sell predictions.
With a target price of 705 € there is a slightly positive potential of 6.72% for Regeneron Pharmaceuticals Inc. compared to the current price of 660.6 €.
So far the community has only identified positive things for Regeneron Pharmaceuticals Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Regeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.

Pros and Cons of Regeneron Pharmaceuticals Inc. in the next few years

Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
S********** s********
?
B****
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Your Opinion
Legal notice

Performance of Regeneron Pharmaceuticals Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Regeneron Pharmaceuticals Inc. -2.650% 0.548% -2.278% 14.608% -0.392% -12.781% 63.758%
IQVIA Holdings Inc. -1.440% 2.177% 0.738% -6.534% -22.216% -18.022% -10.702%
Incyte Corp. -0.420% 2.031% -5.018% 44.224% -3.348% 22.112% 15.494%
Exact Sciences 1.350% 0.000% 2.647% 120.832% 4.865% 45.138% -19.378%

Comments

Prediction Buy
Perf. (%) -0.84%
Target price 697.831
Change
Ends at 31.03.27

Regeneron Pharmaceuticals (REGN) had its price target lowered by Truist Financial Corporation from $818.00 to $801.00. They now have a "buy" rating on the stock.
Ratings data for REGN provided by MarketBeat
Show more

Truist Financial Co. 
0
Report Share
31.03.26
Prediction Buy
Perf. (%) -0.87%
Target price 762.300
Change
Ends at 31.03.27

Regeneron Pharmaceuticals (REGN) is now covered by Piper Sandler. They set an "overweight" rating and a $875.00 price target on the stock.
Ratings data for REGN provided by MarketBeat
Show more

Piper Sandler 
0
Report Share
31.03.26
Prediction Buy
Perf. (%) 1.35%
Target price 794.334
Change
Ends at 06.03.27

Regeneron Pharmaceuticals (REGN) is now covered by Barclays PLC. They set an "overweight" rating and a $923.00 price target on the stock.
Ratings data for REGN provided by MarketBeat
Show more

Barclays PLC 
0
Report Share
06.03.26
Show more
Not a member yet? Sign up for free!

News

Regeneron Pharmaceuticals: A Strong Contender in the Biotech Arena: https://g.foolcdn.com/editorial/images/862492/mqdefault-2026-03-26t075718308.jpg
Regeneron Pharmaceuticals: A Strong Contender in the Biotech Arena

Explore the exciting world of Regeneron Pharmaceuticals (NASDAQ: REGN) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable

TheMotleyFool 
0 31.03.26
Is Regeneron a Multimillionaire-Maker Stock?: https://g.foolcdn.com/editorial/images/862097/person-raising-two-fists-in-the-air.jpg
Is Regeneron a Multimillionaire-Maker Stock?

Regeneron (NASDAQ: REGN) has encountered several headwinds over the past two years, including the loss of patent exclusivity for one of its growth drivers, Eylea, a medicine for wet age-related

TheMotleyFool 
0 27.03.26
Is Eli Lilly's Weight Loss Empire in Trouble?: https://g.foolcdn.com/editorial/images/860445/person-sitting-at-a-desk-looking-at-two-monitors.jpg
Is Eli Lilly's Weight Loss Empire in Trouble?

Over the past two years, Eli Lilly (NYSE: LLY) has established itself as the leader in the weight loss market. That's thanks to the company's tirzepatide, a compound sold under the brand name

TheMotleyFool 
0 13.03.26